Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc Receives FDA Approval For Juvederm Voluma XC


Wednesday, 23 Oct 2013 04:51pm EDT 

Allergan, Inc announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM VOLUMA XC, the first and only filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. JUVEDERM VOLUMA XC helps create a more youthful appearance to the face and provides natural-looking and long-lasting results up to two years with optimal treatment. 

Company Quote

212.63
0.45 +0.21%
19 Dec 2014